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Highlights 28 
• NF-kB and MYC co-activation originates (pre)plasmablast-like cancer   29 
• NF-kB/MYC+ renders cancer cells addicted to IL6 for survival and phenotypic stability 30 
• NF-kB/MYC+ cancers are alike a fraction of human plasmablastic lymphoma  31 
• t(8;14)[MYC- IGH] multiple myeloma is linked to a NF-kB/MYC co-activation signature  32 
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Summary 34 
NF-kB and MYC are found co-deregulated in human B and plasma-cell cancers. In physiology, NF-kB is 35 
necessary for terminal B-to-plasma cell differentiation, whereas MYC repression is required. It is thus 36 
unclear if NF-kB/MYC co-deregulation is developmentally compatible in carcinogenesis and/or impacts 37 
cancer cell differentiation state, possibly uncovering unique sensitivities. Using a mouse system to trace 38 
cell lineage and oncogene activation we found that NF-kB/MYC co-deregulation originated cancers with a 39 
plasmablast-like phenotype, alike human plasmablastic-lymphoma and was linked to t(8;14)[MYC-40 
IGH]  multiple myeloma. Notably, in contrast to NF-kB or MYC activation alone, co-deregulation rendered 41 
cells addicted to IL6 for survival and phenotypic stability. We propose that conflicting oncogene-driven 42 
differentiation pressures can be accommodated at a cost in poorly-differentiated cancers. 43 
 44 
Significance 45 
Our studies improve the understanding of cancer pathogenesis by demonstrating that co-deregulation of 46 
NF-kB and MYC synergize in forming a cancer with a poorly-differentiated state. The cancers in the mouse 47 
system share features with human Plasmablastic lymphoma that has a dismal prognosis and no standard of 48 
care, and with t(8;14)[MYC-IGH] Multiple myeloma, which is in overall resistant to standard therapy. 49 
Notably, we found that NF-kB and MYC co-deregulation uniquely render cells sensitive to IL6 deprivation, 50 
providing a road-map for patient selection. Because of the similarity of the cancers arising in the compound 51 
mutant mouse model with that of human Plasmablastic lymphoma and t(8;14)[MYC-IGH] Multiple 52 
myeloma, this model could serve in preclinical testing to investigate novel therapies for these hard-to-treat 53 
diseases. 54 
 55 
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Introduction 68 
Diffuse-large-B-cell-lymphoma (DLBCL) and Multiple myeloma (MM) are the most frequent 69 
hematological malignancies overall, each comprising multiple disease entities with different genetic 70 
profiles and response to treatment (Kumar et al., 2017; Young et al., 2019). There is no clear interconnection 71 
between these two diseases and reports of co-occurrence are extremely rare. However, DLBCL and MM 72 
share the same normal cell counterpart albeit at different stages of differentiation, i.e. a mature B-cell and 73 
a terminally-differentiated B-cell (Plasma-cell), respectively. 74 
 75 
B-to-plasma cell differentiation is a multi-stage process that involves an intricate network of factors. It 76 
initiates through the downregulation of PAX5 in an activated B-cell, a transcription factor critical for B-cell 77 
identity, allowing the expression of factors such as XBP1 and JCHAIN (Nutt et al., 2015). Subsequent 78 
upregulation of BLIMP1 and IRF4 expression, at least in part downstream of the NF-kB pathway, is key 79 
for the reinforcement of the plasma-cell program and full terminal B-cell differentiation characterized by 80 
cell cycle arrest and substantial Ig secretion (Grumont and Gerondakis, 2000; Heise et al., 2014; Klein et 81 
al., 2006; Morgan et al., 2009; Nutt et al., 2015; Saito et al., 2007). 82 
 83 
Notably, genetic alterations leading to the activation of the NF-kB pathway are found in ~40% of DLBCLs 84 
corresponding primarily to the so-called activated B-cell subset (ABC-DLBCL) and in about 20% of MM 85 
patients (Annunziata et al., 2007; Compagno et al., 2009; Davis et al., 2010; Keats et al., 2007; Lenz et al., 86 
2008a). However, in more than 80% of cases, MM cancer cells constitutively engage the NF-kB pathway 87 
through stimuli received from the cancer microenvironment (Demchenko and Kuehl, 2010; Hideshima et 88 
al., 2005; Staudt, 2010). NF-kB signaling plays a crucial role in the survival of mature B-cells and Plasma-89 
cells in physiology and pathology and is critical for both ABC-DLBCL and MM cell lines (Staudt, 2010; 90 
Tornatore et al., 2014). 91 
 92 
The knowledge that NF-kB directly induces the expression of genes essential in B-to-plasma cell 93 
differentiation and that ABC-DLBCL cancer cells despite being mature B-cells display features of 94 
plasmacytic differentiation suggest that a block of B-to-plasma cell is required in the pathogenesis of ABC-95 
DLBCL. Consistently, the activity of BLIMP1, key for B-to-plasma cell differentiation, is lost exclusively 96 
in DLBCL of the ABC subtype through BLIMP1 genetic aberrations (∼30% of cases), and indirectly by 97 
deregulated BCL6 expression from chromosomal translocations (∼26% of cases) (Mandelbaum et al., 98 
2010; Pasqualucci et al., 2011; Tam et al., 2006; Zhang et al., 2015). We and others previously demonstrated 99 
using mouse models that disruption of Blimp1 precluded B-to-Plasma cell differentiation and synergized 100 
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with NF-kB activation for the development of lymphomas resembling ABC-DLBCL (Calado et al., 2010; 101 
Mandelbaum et al., 2010; Zhang et al., 2015).  102 
 103 
The expression of the proto-oncogene MYC is deregulated through diverse mechanisms in most cancers, 104 
including ABC-DLBCL and MM (Anderson, 2011; Janz, 2006; Shaffer et al., 2006). In fact, around 70% 105 
of ABC-DLBCLs and at least 40% of MMs display MYC positivity at the protein level (Hu et al., 2013; 106 
Szabo et al., 2016; Xiao et al., 2014). Amongst other properties, MYC has a crucial role in regulating cell 107 
cycle entry of mammalian cells in both physiology and pathology and is critical in both ABC-DLBCL and 108 
MM cell lines(Holien et al., 2012; Lenz et al., 2008b; Shaffer et al., 2008). 109 
The survival properties of the NF-kB pathway, and MYC’s role in cell cycle, favor the hypothesis that these 110 
factors are synergistic in carcinogenesis. However, it may be important in this hypothesis to account for 111 
specific oncogene-driven differentiation pressures. In fact, and in contrast to the key role of NF-kB in 112 
Plasma-cell differentiation it has been shown that MYC opposes this process and that MYC expression is 113 
repressed by BLIMP1 for terminal B-cell differentiation to ensue (Lin et al., 2000; Lin et al., 1997; Shaffer 114 
et al., 2002). It is thus unclear whether co-deregulation of NF-kB and MYC is developmentally compatible 115 
for carcinogenesis, and whether a potential synergy impacts the differentiation state of cancer cells, possibly 116 
uncovering unique sensitivities. 117 
 118 
In this work we used a system in the mouse to trace cell lineage and oncogene activation and found that co-119 
deregulation of NF-kB and MYC synergize to form cancer with a poorly-differentiated Plasma-cell state. 120 
The mouse cancers resembled a fraction of human Plasmablastic lymphoma, a rare disease with a dismal 121 
prognosis, and were linked at the gene expression level with MM carrying t(8;14)[MYC-IGH] that are in 122 
overall resistant to standard therapy(Montes-Moreno et al., 2010; Valera et al., 2010). In contrast to 123 
activation of either NF-kB or MYC alone, co-deregulation rendered cells sensitive to IL6 deprivation, and 124 
in the absence of IL6 the synergy between NF-kB and MYC in the formation of a cancer with a poorly-125 
differentiated Plasma-cell state was lost. This work evidences that poorly-differentiated cancer cells can 126 
accommodate conflicting oncogene-driven differentiation pressures at the cost of a critical dependency. 127 
 128 
 129 
 130 
 131 
 132 
 133 
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Results 135 
Experimental design 136 
To investigate the oncogenic activity of constitutively active NF-kB signaling and MYC over-expression, 137 
alone or in combination, we used the CD19creERT2 transgene that targets Cre expression in B cells 138 
encompassing all stages of development except terminally differentiated B-cells (Plasma-cells) in a 139 
temporally regulated manner through tamoxifen administration (Fig. 1)(Yasuda et al., 2013). To induce 140 
activation of the NF-kB canonical pathway and/or MYC over-expression we generated compound mutant 141 
mice carrying the CD19creERT2 allele together with a ROSA26 allele IKK2castopFL and/or a ROSA26 allele 142 
containing a MYC cDNA driven by a CAG promoter (Fig. 1A; MYCstopFL; (Calado et al., 2012; Sasaki et 143 
al., 2006)). Activation of the IKK2castopFL allele by Cre-mediated recombination can be traced by expression 144 
of GFP, whereas activation of the MYCstopFL allele is marked by expression of a signaling deficient truncated 145 
version of human CD2 (Fig. 1A). Mice carrying the CD19creERT2 transgene in combination with a ROSA26 146 
reporter allele containing a cDNA encoding YFP preceded by a loxP flanked STOP cassette (YFPstopFL; 147 
(Srinivas et al., 2001)) were used as controls (Fig. 1B). 148 
 149 
CD19creERT2 allows the study of oncogenic mutations alone and in combination in a single mouse 150 
In a bona fide model system of cancer the introduction of oncogenic mutations are tissue specific, 151 
temporally controlled, to trace the fate of cells in which mutations were introduced, and restricted to a small 152 
number of cells, mimicking the sporadic nature of oncogenic events. The ability to test the outcome of 153 
multiple oncogenes alone and in combination in the same mouse at the same time would be ideal to 154 
investigate synergy, dysergy or neutrality. We first immunized CD19creERT2 IKK2castopFL MYCstopFL 155 
(hereafter termed C-IM) and control CD19creERT2 YFPstopFL (hereafter termed C-YFP) mice and injected 156 
tamoxifen at days 6, 7, 8, and 9 after immunization (Fig. 1C). Analysis at day 10 after the 1st tamoxifen 157 
injection (i.e. at day 15 after immunization) revealed that control mice had a small fraction of YFP+ (~2%) 158 
in the spleen (Fig. 1D). C-IM mice on other hand had three Cre-recombined populations: GFP+hCD2neg 159 
cells (~1%) representing cells with constitutive NF-kB activation alone, GFPneghCD2+ cells (~1%) 160 
representing cells where only MYC activation occurred, and GFP+hCD2+ (~0.5%) representing cells 161 
carrying both mutations (Fig. 1D). The Cre-recombined populations in C-YFP and C-IM mice were  162 
overwhelmingly B-cells (Fig. 1D). We concluded that the CD19creERT2 system displays ideal properties to 163 
investigate the function of oncogenic events in carcinogenesis. 164 
 165 
NF-kB signaling and MYC over-expression synergize for hyperplasia of a Plasma-cell like population 166 
To determine the impact of enforced NF-kB activation and MYC over-expression on B-cell fate, we 167 
established cohorts of control C-YFP mice, of experimental C-IM mice and mice carrying the CD19creERT2 168 
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allele in combination with either the IKK2castopFL allele (hereafter termed C-IKK2) or MYCstopFL (hereafter 169 
termed C-MYC) in accord with the experimental design in (Fig. 1C). We first examined the blood of mice 170 
for reporter positive cells at 55 days after the 1st tamoxifen injection and multiple timepoints thereafter to 171 
trace their persistence or disappearance. The fractions of YFP+ cells in C-YFP and of MYC single 172 
expressing cells in C-MYC and C-IM decayed over the time of analysis, whereas the cellular population 173 
with enforced NF-kB activation in C-IKK2 and C-IM remained constant (Fig. S1A-C). In contrast, the 174 
fraction of cells in which NF-kB and MYC were co-deregulated increased over the time of analysis (Fig. 175 
S1A and B). These data suggest that co-deregulation of NF-kB and MYC promote cellular expansion. 176 
We next analyzed the spleens of mice at day 55 and 95 after tamoxifen injection and characterized 177 
phenotypically the reporter positive populations using flow-cytometry. Similarly to the analysis at day 10 178 
(Fig. S1D) we found at these time-points a YFP+ population in C-YFP mice and three distinct reporter 179 
positive populations: GFPneghCD2+ i.e. MYC+, GFP+hCD2neg i.e. IKK2ca+, and GFP+hCD2+ i.e. 180 
IKK2ca+MYC+ (Fig. 1E and F). In contrast to the analysis at day 10, the IKK2ca+MYC+ population was at 181 
day 55 of analysis no longer homogenous with two distinct subpopulations emerging at day 95 (Fig. 1E 182 
and F). Further analysis using B-cell and Plasma-cell markers revealed the appearance of Plasma-cell like 183 
cells (CD19lowCD138+), being particularly noticeable within IKK2ca+MYC+ cells (~10% at day 55; ~50% 184 
at day 95) compared to the other reporter positive cell populations (Fig. 1E and F). This data showed that 185 
expression of MYC from the MYCstopFL allele did not impair the loss of the B-cell phenotype and acquisition 186 
of Plasma-cell like markers (Lin et al., 2000; Lin et al., 1997). Further, the data demonstrated that NF-kB 187 
signaling and MYC over-expression synergized for hyperplasia of a Plasma-cell like population. 188 
 189 
NF-kB or MYC expression leads to B cell lymphoma while co-deregulation to Plasma-cell like cancers 190 
To assess a role of constitutive NF-kB signaling and MYC over-expression in carcinogenesis we aged 191 
control C-YFP, and experimental mice (C-IKK2, C-MYC, C-IM). C-IM displayed a dramatically reduced 192 
life span due to cancer occurrence (~190 days after tamoxifen injection, p<0.0001) compared to all other 193 
genotypes (Fig. 2A). C-IKK2 and C-MYC mice also succumbed to cancer to a variable degree, albeit at a 194 
much later time-point (~500 days after tamoxifen injection; Fig. 2A). C-MYC and C-IKK2 mice presented 195 
splenomegaly and accumulation of reporter positive cells in the spleen and lymph-nodes (Fig. 2B). In both 196 
cases, the cancer cells expressed the B-cell marker CD19 indicating B-cell lymphoma development (Fig. 197 
2C).  Macroscopic examination of cancer-bearing C-IM mice showed splenomegaly and hepatomegaly 198 
(Fig. 2B, not shown). Cancer-bearing C-IM mice displayed clonal accumulation of IKK2ca+MYC+ cells in 199 
the spleen, liver and bone marrow, with cells carrying single mutations being largely absent (Fig. 2D and 200 
E and S2A, not shown). Cancer cells in C-IM expressed the Plasma-cell marker CD138 (Fig. 2D), and 201 
histological examination of C-IM spleens showed compared to control mice a diffuse cell pattern with loss 202 
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of follicular structure and B220 and Pax5 expression, but positivity for Irf4 and the proliferative marker 203 
Ki67 (Fig. 2F). Further suggesting a Plasma-cell like cancer, C-IM had an aberrant accumulation of IgM 204 
paraprotein (Fig. S2B and C). These data highlighted a unique synergy between NF-kB signaling and MYC 205 
over-expression for the formation of Plasma-cell like cancers.  206 
 207 
Cancers with NF-kB and MYC co-deregulation display a phenotype alike that of (pre)plasmablast 208 
B-to-Plasma cell differentiation is a multi-stage process that involves an intricate network of factors (Fig. 209 
3A, (Nutt et al., 2015)). To characterize the stage of B-to-Plasma cell differentiation of NF-kB+MYC+ 210 
cancer cells we performed gene expression profiling (GEP) by RNA sequencing of FACS-sorted 211 
GFP+hCD2+ cancer cells. We next compared the GEP of cancer cells with that of discrete B-cell and 212 
Plasma-cell populations (Shi et al., 2015). In agreement with the phenotypical characterization (Fig. 2), 213 
NF-kB+MYC+ cancer cells clustered with normal Plasma-cell populations in the loss of the expression of 214 
genes associated with the B-cell phenotype, including Pax5, Ms4a1 (CD20), and CD19 (Fig. 3B, and C). 215 
However, when analyzing genes which expression is increased in a Plasma-cell, the NF-kB+MYC+ cancer 216 
cells displayed an intermediate B-to-Plasma cell GEP, clustering on their own (Fig. 3B). Such an B-to-217 
Plasma cell GEP state was highlighted  by intermediate expression of Blimp1, Irf4, and Xbp1 that are critical 218 
for B-to-Plasma cell differentiation and of other Plasma-cell expressed genes such as CD138 (Sdc1) and 219 
Jchain (Fig. 3B-D). Gene signatures have previously been generated for Plasmablasts and Plasma-cells 220 
(Shi et al., 2015). Using these signatures we performed gene set enrichment analysis (GSEA) and found 221 
that the GEP of C-IM cancer cells was enriched for genes associated with Plasmablasts whereas the GEP 222 
of normal Plasma-cells was enriched for genes present in the Plasma-cell signature (Fig. 3E). These data 223 
suggested that enforced NF-kB activation and MYC over-expression synergized in the development of a 224 
cancer at a poorly-differentiated plasma-cell stage alike that of (pre)plasmablast.  225 
 226 
NF-kB and MYC co-deregulation confers proliferative and survival advantage to (pre)Plasmablasts 227 
To better understand the contribution of NF-kB and MYC co-deregulation we used a classical 228 
(pre)Plasmablast (B220lowCD138+) differentiation assay in vitro in which B-cells are cultured in the 229 
presence of LPS (Andersson et al., 1972). For this purpose, we crossed the IKK2castopFL, MYCstopFL, and 230 
control YFPstopFL alleles with CD19cre that constitutively targets Cre expression in B-cells(Rickert et al., 231 
1997). In agreement with the in vivo data, we found a profound synergy in the accumulation of 232 
B220lowCD138+ cells in cultures derived from CD19cre IKK2castopFL MYCstopFL B-cells  compared to those 233 
where NF-kB or MYC deregulation occurred alone (Fig. 4A and B). Analysis of the fraction of 234 
B220lowCD138+ cells per division revealed an increased proliferative capacity upon NF-kB and MYC co-235 
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deregulation compared to all other genotypes (Fig. 4C). This increased proliferative capacity was 236 
accompanied by reduced apoptosis as measured by cleaved caspase 3 (Fig. 4D). These data showed that 237 
co-deregulation of NF-kB and MYC provided an advantage in proliferative capacity and survival of 238 
(pre)Plasmablasts.  239 
 240 
NF-kB and MYC co-deregulation render cells addicted to IL6 for survival 241 
To uncover dependencies of cancer cells with NF-kB and MYC co-deregulation we compared the GEP of 242 
the C-IM cancer cells with that of normal Plasma-cells. Compared to plasma-cells, the GEP of C-IM cancer 243 
cells was depleted for genes associated with the gene signature “Hallmarks_Apoptosis” (Fig. 5A) and 244 
pathway analysis revealed the enrichment of the “IL6 JAK/STAT” and “IL-6 signaling in MM” signatures 245 
in the GEP of C-IM cancer cells, reflected in part by the reduced expression of the STAT3 pathway inhibitor 246 
Socs3, and increased expression of Il6st, that encodes the IL6 co-receptor gp130 (Fig. 5B-C). The IL6 247 
JAK/STAT pathway was previously shown to play a key role in the survival of MM cancer cells ex vivo 248 
and in vivo (Klein et al., 1990a). IL6 ligation to IL6ra and gp130 leads to STAT3 phosphorylation 249 
(pSTAT3), homodimerization and nuclear translocation where it activates the transcription of multiple 250 
genes including the anti-apoptotic factors BclxL and Mcl1 (Gaudette et al., 2014; Jourdan et al., 2003; 251 
Peperzak et al., 2013). Consistent with previous work demonstrating that IL6 is induced by NF-kB 252 
activation (Libermann and Baltimore, 1990), we found increased IL6 expression in the in vitro cultures 253 
derived from B-cells of mice carrying the IKK2castopFL allele alone or in combination with MYCstopFL (Fig. 254 
S3A). Notably,  IL6 production was highly enriched in the (pre)Plasmablast population (~85% of cells) 255 
compared to the activated B-cell population (~15% of cells; Fig. S3A). To investigate the survival 256 
dependency on IL6 of (pre)Plasmablasts with NF-kB and MYC single or double de-regulation, we cultured 257 
B-cells with LPS in the absence or presence of an anti-IL6 neutralizing antibody (Fig. 5D). Suggestive of 258 
increased dependency and/or selection, the (pre)Plasmablasts with NF-kB and MYC co-deregulation 259 
showed the highest levels of pSTAT3 amongst all genotypes (Fig. 5E). Treatment of the cell cultures with 260 
anti-IL6 was effective in reducing the levels of STAT3 phosphorylation in all genotypes (Fig. 5E). The 261 
proliferative capacity of the (pre)Plasmablasts was unaltered by the anti-IL6 neutralizing antibody(Fig. 262 
S3B). However, we found a significant increase in the fraction of (pre)Plasmablasts marked for apoptosis 263 
in the condition where NF-kB and MYC were co-deregulated and a trend when MYC was deregulated 264 
alone (Fig. 5F). We next looked at the expression of anti-apoptotic proteins known to be downstream of 265 
IL6 signaling. With exception of the (pre)Plasmablasts carrying NF-kB activation alone, IL6 neutralization 266 
led to significant reduction in BclxL protein levels (Fig. 5G), whereas this was the case for Mcl1 protein 267 
levels in (pre)Plasmablasts carrying NF-kB/MYC co-deregulation and deregulation of MYC alone (Fig. 268 
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5H). These data showed that (pre)Plasmablasts with NF-kB and MYC co-deregulation and with 269 
deregulation of MYC alone are particularly sensitive to IL6 deprivation in vitro. Additional analysis by 270 
GEP demonstrated that such sensitivity to IL6 deprivation is (pre)Plasmablast specific, given the unaltered 271 
GEP profile of B cells with NF-kB/MYC co-deregulation upon IL6 neutralization (Fig. 5I and J). To 272 
investigate whether IL6 neutralization delayed cancer occurrence in C-IM mice, we aged cohort of mice 273 
and performed a single course of IL6 neutralization. Injection of anti-IL6 antibody significantly increased 274 
the length of cancer free survival of C-IM mice (Fig. 5K) suggesting a dependency of IKK2ca+MYC+ 275 
cancer cells on IL6 also in vivo.  276 
 277 
IL6 is critical for NF-kB+MYC+ (pre)plasmablast-like cancer phenotypic stability 278 
We next wanted to determine whether IL6 dependency upon NF-kB and MYC co-deregulation was 279 
associated with cellular transformation at a poorly-differentiated Plasma-cell state. For that we generated 280 
compound mutant C-IM mice lacking IL6 (hereafter termed C-IM-IL6KO). Analysis of mice at 100 days 281 
after tamoxifen injection revealed a trend for a reduced fraction of cells with NF-kB and MYC co-282 
deregulation, whereas cells with NF-kB or MYC deregulation alone showed either a trend for increased 283 
fraction of cells or no difference, respectively (Fig. 6A and B). When characterizing the fraction of 284 
CD19lowCD138+ cells (Plasma-cell like) within each reporter positive population the impact of IL6 285 
deprivation was unique to cells carrying NF-kB and MYC co-deregulation both in spleen (Fig. 6C) and 286 
bone marrow (Fig. S4A). Also only in the Plasma-cell like cells within the IKK2ca+MYC+ population we 287 
observed a significant increase in the fraction of cleaved caspase 3 positive  cells (Fig. 6D). In contrast, IL6 288 
deprivation had little impact on the cell cycle status of CD19lowCD138+ cells within the IKK2ca+MYC+ 289 
population, whereas a slight increase in cells at the S/G2M phase was observed in the MYC activation alone 290 
condition (Fig. 6E). These data showed that NF-kB and MYC co-deregulation uniquely rendered cells 291 
sensitive to IL6 deprivation in vivo. These data also suggest that the apparent dependency of 292 
(pre)Plasmablasts with MYC deregulation alone on IL6 in vitro (Fig. 5F and H) could be a consequence of 293 
LPS induced NF-kB activation. 294 
To investigate if IL6 had a role in the synergy between NF-kB and MYC in cell transformation we generated 295 
cancer cohorts of  C-IM mice and C-IM-IL6KO mice following the previously described protocol of study 296 
(Fig. 1B). Compared to C-IM mice, C-IM-IL6KO had significantly prolonged cancer latency, with a median 297 
survival of 265 day for C-IM-IL6KO compared to 187 for C-IM (Fig. 6F). Notably, C-IM-IL6KO cancers 298 
had a significant increased fraction of cleaved caspase 3 positive cells compared to C-IM cancers and were 299 
enriched in their gene GEP for the gene signature “Hallmark_Apoptosis” (Fig. 6G and H).  To better 300 
characterize the state of B-to-Plasma cell differentiation of C-IM-IL6KO cancer cells we performed GEP 301 
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by RNA sequencing of FACS-sorted GFP+hCD2+ cancer cells and compared their GEP with that of discrete 302 
B-cell and Plasma-cell populations (Shi et al., 2015). Two out of 6 C-IM-IL6KO cancers analyzed by 303 
RNAseq clustered with the B-cell populations in the expression of genes associated with the B-cell 304 
phenotype, whereas 4/6 C-IM-IL6KO cancers clustered together with the C-IM cancers and the Plasma-cell 305 
populations in the loss of the expression of genes associated with the B-cell phenotype (Fig. 6I). 306 
Histological analysis revealed that roughly 15% (3/21) of C-IM-IL6KO cancers presented a B-cell like 307 
phenotype (Fig. S4B). When analyzing genes which expression is increased in Plasma-cells the four C-IM-308 
IL6KO that for the B-cell signature clustered with C-IM no longer grouped together with these cancers (Fig. 309 
6I). Whereas C-IM-IL6KO cancers clustered with the Plasma-cell populations (Fig. 6I), the C-IM cancers, 310 
as before (Fig. 3B) had an intermediate B-to-Plasma cell GEP, clustering on their own (Fig. 6I). Compared 311 
to C-IM cancers the C-IM-IL6KO B-cell like cancers had in a accordance to their phenotype reduced 312 
expression of Blimp1, Irf4, and Xbp1, whereas expression of Pax5 was elevated (Fig. 6K and L). The C-313 
IM-IL6KO Plasma-cell like cancers were depleted in genes characteristically expressed by Plasmablasts 314 
compared to C-IM cancers (Fig. 6M), and had increased expression of Blimp1 (Fig. 6N). These data suggest 315 
that compared to the C-IM cancers, the C-IM-IL6KO Plasma-cell like cancers were more alike a well-316 
differentiated Plasma-cell. In summary, IL6 was critical in the synergy between NF-kB and MYC 317 
deregulation for survival and transformation of a cell with a poorly-differentiated Plasma-cell phenotype. 318 
Phenotypic stability 319 
 320 
In the context of NF-kB activation MYC interferes with the expression of Plasma-cell factors 321 
Previous work in cell lines suggested that repression of MYC by BLIMP1 is necessary for B cell terminal 322 
differentiation (Lin et al., 2000; Lin et al., 1997). In this work we showed that MYC over-expression driven 323 
from the MYCstopFL allele does not interfere with the loss of the B-cell phenotype (Fig. 3 and 4). To better 324 
understand how MYC overexpression may interfere with the state of Plasma-cell differentiation we 325 
performed LPS stimulation of B-cells in vitro that either carrying NF-kB deregulation alone or together 326 
with MYC. We next purified reporter positive B220lowCD138+ cells from these cultures and performed GEP 327 
using RNA-seq. Comparison of these GEP with previously derived Plasmablast and Plasma-cell signatures 328 
revealed that the GEP of cells with NF-kB and MYC co-deregulation was enriched for genes present in the 329 
Plasmablast signature whereas the GEP of cells with NF-kB deregulation alone enriched for genes present 330 
in the Plasma-cell signature (Fig. 7A). In agreement with these data cells with NF-kB deregulation alone 331 
expressed higher levels of genes key for the Plasma-cell differentiation process, namely Blimp1, Irf4, and 332 
Xbp1 compared to cells with NF-kB and MYC co-deregulation (Fig. 7B). The level of the B-cell identity 333 
gene Pax5 were identical between genotypes (Fig. 7B). These data indicates that MYC overexpression did 334 
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not impact the loss of the B-cell phenotype, but it interfered with the reinforcement of the Plasma-cell 335 
program curtailing full Plasma-cell differentiation. 336 
 337 
C-IM cancers are alike a fraction of plasmablastic lymphoma 338 
We next investigated if the cancers occurring in the C-IM mice resembled human disease. We excluded 339 
human-ABC-DLBCLs given that these lymphomas retain the B-cell phenotype in the vast majority of 340 
cells(Alizadeh et al., 2000). PBL on other hand is a human cancer that carries a Plasmablast-like phenotype 341 
and in which B-cell markers have been lost, despite being classified under DLBCL (Montes-Moreno et al., 342 
2010; Swerdlow, 2008; Valera et al., 2010). Notably, at least 70% of PBL cases carry Ig/MYC 343 
translocations or MYC locus gain, and a recent PBL patient derived cell line was shown to be IL6 dependent 344 
(Mine et al., 2017; Taddesse-Heath et al., 2010; Valera et al., 2010). The C-IM cancers were generated 345 
through MYC overexpression, displayed a critical dependency on IL6 and had a poorly-differentiated 346 
Plasma-cell state similar to that of a (pre)Plasmablast. However, for the development of cancers in the 347 
mouse model system we also enforced the activation of the NF-kB pathway and currently it is unknown if 348 
PBL displays constitutive NF-kB signaling. We therefore assembled a cohort of 34 PBL cases and 349 
performed immunohistochemistry to determine MYC positivity, activation of the NF-kB canonical and 350 
alternative pathway through determination of nuclear p50 and p52, respectively, and activation of the 351 
STAT3 pathway using an anti-pSTAT3 antibody (Compagno et al., 2009). All of PBL cases analyzed were 352 
strongly positive for MYC, whereas ~15% (5/33) were positive for nuclear p50, ~25% (8/33) were positive 353 
for nuclear p52, and ~15% (6/33) were positive for both, suggesting that ~55% (19/33) of PBL cases in the 354 
study cohort display activation of the NF-kB pathway (Fig 7C). We also found that ~44% (15/34) of PBL 355 
cases in the study cohort displayed phosphorylated STAT3 (Fig 7C). In summary, ~28% (9/32) of PBL 356 
cases in the assembled cohort displayed co-deregulation of NF-kB, MYC and STAT3 phosphorylation (Fig 357 
7C), indicating that the C-IM cancers are alike a fraction of PBL cancers. 358 
 359 
NF-kB and MYC co-deregulation identifies multiple myeloma patients with poor prognosis 360 
We investigated whether oncogene associated gene signatures could also be predictive of patient outcome. 361 
Signatures associated with NF-kB or STAT3 activation were per se not predictive of patient outcome (Fig. 362 
S5A and B). In contrast, we found that signatures associated with MYC activity were highly predictive of 363 
patient outcome, in agreement to what was previously found at the protein level by others ((Moller et al., 364 
2018); Fig. S5C). The lack of predictive value of both NF-kB or STAT3 gene signatures was puzzling. We 365 
therefore performed GEP of B220lowCD138+ cells derived in vitro from B-cells without oncogene activation 366 
and with NF-kB and MYC deregulation alone or together. We next generated signatures of upregulated 367 
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genes unique to each genotype i.e. specific to a condition where only enforced NF-kB occurred  368 
(IKK2.muTex), where only MYC de-regulation was induced (Myc.muTex), and for the condition where 369 
both NF-kB and MYC were enforced simultaneously (Myc.IKK2.muTex; Fig S5D). In contrast to the NF-370 
kB and STAT3 gene signatures, all three muTex signatures were highly predictive of overall survival (OS) 371 
and progression free survival (PFS) (Fig. 7D and S5E and F). Notably, each muTex gene signature 372 
specifically enriched into discrete MM subsets according to their hallmark translocations (Fig. 7E and S5E  373 
and F). MM cases carrying either t(14;16)[IGH-MAF] or t(4;14)[FGFR3/WHSC1-IGH] positively 374 
correlated in their GEP with the IKK2.muTex signature whereas a negative correlation with this signature 375 
was observed for MM cases carrying t(8;16)[MYC-IGH] (Fig. S5E). The Myc.muTex gene signature was 376 
found to be significantly enriched in MM cases carrying t(6;14)[CCND3-IGH] (Fig. S5F), and the 377 
Myc.IKK2.muTex gene signature was significantly enriched in MM cases carrying t(8;16)[MYC-IGH] 378 
(Fig. 7E). These data suggest that gene signatures generated from phenotypically relevant cells with 379 
enforced NF-kB and MYC single and co-deregulation identify MM patients with poor prognosis and were 380 
linked to discrete genomic alterations providing a road-map for patient selection in specific therapeutic 381 
settings. The observation that a signature unique to NF-kB and MYC co-deregulation associates with MM 382 
carrying t(8;16)[MYC-IGH] indicates a role for the NF-kB and IL6 signaling pathway in these hard to treat 383 
MM patient subset.  384 
 385 
 386 
 387 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
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Discussion 402 
In this work we studied oncogenic events that in physiology impose conflicting differentiation pressures. 403 
Specifically, we investigated carcinogenesis upon activation of NF-kB and MYC in the context of B-to-404 
Plasma cell differentiation. We found that NF-kB and MYC co-deregulation synergized for the 405 
development of a cancer with a phenotype of a poorly-differentiated Plasma-cell, resembling a 406 
(pre)Plasmablast. Notably, in contrast to single NF-kB or MYC activation, co-deregulation rendered cells 407 
sensitive to IL6 deprivation, and IL6 was critical for the NF-kB/MYC synergy in forming a cancer with a 408 
poorly-differentiated Plasma-cell phenotype. We propose that poorly-differentiated cancer cells can 409 
accommodate at a cost conflicting oncogene-driven differentiation pressures. 410 
  411 
The current work provides cues for the order and timing of mutation acquisition in the pathogenesis of 412 
mature B-cells. The finding that B-cell specific co-deregulation of NF-kB and MYC originates cancers 413 
devoid of B-cell markers supports that a block in B-to-Plasma cell differentiation, such as loss of BLIMP1 414 
activity, is required for the pathogenesis of ABC-DLBCL. Given that cancer cells in ABC-DLBCL retain 415 
the B-cell phenotype, the cancers the current mouse model are not alike ABC-DLBCL. Instead, the NF-416 
kB/MYC mouse cancers seem alike a fraction of human PBL and are linked with t(8;14)[MYC-IGH] MM 417 
at the gene expression level. We found that ~55% of PBLs display NF-kB and MYC activation, and others 418 
have shown that a Plasmablastic morphology in MM is linked to high MYC expression and dismal survival 419 
prognosis (Lorsbach et al., 2011; Moller et al., 2018). 420 
 421 
Surprisingly, BLIMP1 genetic aberrations are also found in a fraction of PBL and MM (Chapman et al., 422 
2011; Montes-Moreno et al., 2017). Their impact on BLIMP1 activity, timing of occurrence, disease 423 
formation and/or progression requires investigation. However, it is tempting to speculate that partial loss 424 
of BLIMP1 activity could alter the transcriptional landscape of cancer cells impacting the differentiation 425 
state and expression of cell cycle genes such as MYC (Montes-Moreno et al., 2017; Shaffer et al., 2008). 426 
Interestingly, BLIMP1 genetic aberrations associate with poor prognosis in MM (Solimando et al., 2019). 427 
 428 
Seminal work by Potter and colleagues described the development of Plasma-cell like cancers in mice upon 429 
pristane injection (Anderson and Potter, 1969). Additional studies revealed that the occurrence of such 430 
cancers involves chronic inflammation, IL6 signaling and the formation of Myc chromosomal translocations 431 
(Cheung et al., 2004; Dechow et al., 2014; Hilbert et al., 1995; Potter et al., 1985; Potter and Wiener, 1992; 432 
Rutsch et al., 2010; Suematsu et al., 1992). Other work showed that activation of MYC in B-cells to mostly 433 
originates cancers with a B-cell phenotype, although some mouse models displayed also Plasma-cell like 434 
cancers in a fraction of cases (Chesi et al., 2008; Harris et al., 1988; Kovalchuk et al., 2000; Park et al., 435 
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2005). It is accepted that NF-kB induces and is induced by inflammatory signals being considered the key 436 
link between inflammation and carcinogenesis (Taniguchi and Karin, 2018). However, despite this 437 
knowledge and that NF-kB favors B-to-Plasma cell differentiation, direct evidence of the participation of 438 
this pathway for the development of Plasma-cell like cancers was missing. Therefore, the current work 439 
provides a rationale for Plasma-cell like carcinogenesis in previous mouse models. The resemblance of the 440 
NF-kB/MYC mouse cancers with a fraction of PBLs and t(8;14)[MYC-IGH] MM indicates a role for the 441 
NF-kB pathway in the pathogenesis and/or progression of the cancers.  442 
 443 
Our work and that of others suggests that knowledge on the differentiation state of cancer cells with respect 444 
to the normal cell counterpart allows a better definition of risk and of therapeutic opportunities (Paiva et 445 
al., 2017; Tarte et al., 2003). Human PBL and t(8;14)[MYC-IGH] MM patients have very poor prognosis 446 
and limited treatment options. The similarity of the NF-kB/MYC mouse cancers with these diseases may 447 
allow their use to identify therapeutic opportunities and strategies. We showed that a single course of anti-448 
IL6 treatment was beneficial in delaying cancer progression. Supporting a possible role for IL6 in PBL, is 449 
the observation that this cytokine was required for the growth of a patient derived cell line (Mine et al., 450 
2017). In MM, Inhibition of IL6 activity is of long-standing interest (Matthes et al., 2016). Initial proof of 451 
principle studies were highly promising, however, the results from randomized trials were unconvincing 452 
(Chari et al., 2013; Klein et al., 1991; Kurzrock et al., 2013; San-Miguel et al., 2014; Voorhees et al., 2013). 453 
It is possible that the results of randomized trials reflect existing MM cancer cell heterogeneity and the co-454 
occurrence of IL6 dependent and independent clones (San-Miguel et al., 2014). This hypothesis is supported 455 
by work demonstrating that IL6 is not crucial in physiology for the survival of all Plasma-cells (Cassese et 456 
al., 2003). We found that B220lowCD138+ cells carrying single MYC or NF-kB deregulation were IL6 457 
independent in vivo. However, the failure of randomized trials and success of proof of principle studies 458 
could be at least in part due to patient selection (Klein et al., 1991; Klein et al., 1990b). Given this 459 
knowledge and the low toxicity of anti-IL6 treatment, although not curative, IL6/IL6R blocking may still 460 
be beneficial for a fraction of relapsed/refractory MM patients, particularly those displaying 461 
(pre)Plamablastic features and/or carrying t(8;14)[MYC-IGH]. 462 
 463 
 464 
 465 
 466 
 467 
 468 
 469 
.CC-BY-NC-ND 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted April 13, 2020. . https://doi.org/10.1101/2020.04.12.038414doi: bioRxiv preprint 
 15 
Figure Legends 470 
Figure 1. NF-kB signaling and MYC over-expression synergize for hyperplasia of a Plasma-cell like 471 
population. See also Fig S1. 472 
(A-B) Scheme illustrating the genetic systems used in the study. Triangles represent loxP sites. R26p and 473 
CAGp represent Rosa26 promoter and CAG promoter. (B) Schematic representation of the protocol of the 474 
study. Black arrow: immunization time-point with sheep red blood cells (SRBC); red arrow: day counting 475 
after the first tamoxifen administration; Blue arrow: tamoxifen administration time-point;  yellow arrow: 476 
analysis time-point. (D-F) Representative flow cytometric analysis of Cre-mediated recombination in C-477 
YFP and C-IM mice at day 10 (D), day 55 (E) and day 100 (F) after the first tamoxifen administration. 478 
Histograms represent CD19 expression within the recombined populations and bottom panels illustrate B-479 
cell (CD19+) and Plasma-cell like (CD19lowCD138+) populations within the individual reporter positive 480 
populations: GFPneghCD2+ i.e. MYC+, GFP+hCD2neg i.e. IKK2ca+, and GFP+hCD2+ i.e. IKK2ca+MYC+.  481 
 482 
Figure 2. NF-kB or MYC expression leads to B cell lymphoma while co-deregulation to Plasma-cell 483 
like cancers. See also Fig S2. 484 
(A) Cancer free survival curve for control C-YFP mice, and experimental C-IKK2, C-MYC, and C-IM mice. 485 
(B) Representative images of spleen and mesenteric lymph nodes from aged mice of the indicated 486 
genotypes. (C) Representative flow cytometric analysis of cancers in spleen of  C-MYC and C-IKK2 mice. 487 
Left panels of each genotype show the frequency of reporter positive cells in the spleen; right panels of 488 
each genotype show the expression of CD19 within reporter positive cells (red), and total splenocytes from 489 
a control C57BL6 mouse (grey). (D) Representative flow cytometric analysis of cancers in spleen and bone 490 
marrow of C-IM mice. Left panels on each tissue show the frequency of double reporter positive cells; right 491 
panels on each tissue show the expression of the plasma cell marker CD138 within the double reporter 492 
positive population (red), and within the reporter negative population (grey). (E) Analysis of clonality by 493 
RNA sequencing. The fraction of reads mapped to each individual IgH-V gene out of all the reads mapped 494 
to IgH-V genes is shown. Top panel: control plasma cells (Shi et al., 2015), bottom panel: GFP+hCD2+ C-495 
IM cancer cells (FACS purified). (F) Representative histological and immunohistochemical analysis of a 496 
C-YFP control spleen (top panels) and of a cancer in the spleen of C-IM mice (bottom panels) for H&E, 497 
B220, Pax5, Irf4, and Ki67. 498 
 499 
Figure 3. Cancers with NF-kB and MYC co-deregulation display a poorly-differentiated Plasma-cell 500 
state. 501 
(A) Schematic representation of the Plasma-cell differentiation process highlighting discrete populations 502 
and the associated expression of B-cell and Plasma-cell factors throughout the process. (B) Transcriptional 503 
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analysis of C-IM cancers compared to discrete B-cell and Plasma-cell populations by RNAseq. GCB: 504 
Germinal Center B-cells, B1: B1 B-cells, FOB: Follicular B-cells, MZB: Marginal Zone B-cells, SPLPC: 505 
Spleen Plasma-cells, BMPC: Bone Marrow Plasma-cells, SPLPB: Spleen Plasmablasts (Shi et al., 2015). 506 
Seven C-IM cancers are depicted.  B-cell signature: expression profile of the top 50 downregulated genes 507 
in BMPCs compared with FOBs, Plasma-cell signature: expression profile of the top 50 upregulated genes 508 
in BMPCs compared to FOBs, in addition to 4 genes of particular immunological interest (Slc3a2, Prdm1, 509 
Ly6c1, Cd28). Log2 FPKM expression values of genes are shown in the heatmaps, color-coded according 510 
to the legend. (C) RNAseq expression data for genes involved in B-cell identity and function (Pax5, Ms4a1, 511 
CD19) and factors related to Plasma-cell differentiation (Prdm1, Irf4, Xpb1, Sdc1, Jchain), in the 512 
populations mentioned in (B). TPM, transcripts per million. (D) Quantitative RT-PCR for plasma cell 513 
differentiation factors in seven C-IM cancers and spleen CD19lowCD138+ plasma cells from C57BL6 mice. 514 
Data was normalized to a house-keeping gene (Hprt1) and then to the expression on naïve B cells (2e-515 
DDCt). 516 
 517 
Figure 4. NF-kB and MYC co-deregulation confers proliferative and survival advantage to 518 
(pre)Plasmablasts. 519 
(A) Representative flow cytometric analysis of the proliferation profiles illustrating the frequency of 520 
(pre)plasmablasts (CD138+) on day 3 of LPS stimulation of B-cells from the indicated genotypes in vitro. 521 
Cell Trace Violet (CTV) dye dilution was used to assess proliferation. (B) Cell numbers of B220lowCD138+ 522 
(pre)plasmablasts recovered from in vitro cultures at the indicated time-points. Black dashed lines represent 523 
control mice (control), yellow solid lines CD19cre IKK2castopFL mice (IKK2ca), blue solid lines CD19cre 524 
MYCstopFL (MYC), and red solid lines CD19cre IKK2castopFL MYCstopFL (IKK2caMYC). (C) Distribution of 525 
B220lowCD138+ (pre)plasmablasts within each cell division as assessed by CTV dilution at day 4 of in vitro 526 
cultures. Mice genotypes are represented as in (B). (D) Frequency of cleaved caspase-3+ within 527 
CD19lowCD138+ in spleen of mice assessed by ex vivo intracellular flow cytometric analysis. Mice of the 528 
indicated genotypes were analyzed between 16 and 29 weeks of age. 529 
 530 
Figure 5. NF-kB and MYC co-deregulation render cells addicted to IL6 for survival. See also Fig S3. 531 
(A) Enrichment for genes in the signature “Hallmark_Apoptosis” using GSEA and the GEP of spleen 532 
CD19lowCD138+ Plasma-cells from C57BL6 mice and C-IM cancer cells. (B) Pathway analysis enrichment 533 
(Metacore) of the GEP of C-IM cancer cells compared to spleen CD19lowCD138+ Plasma-cells. The top 5 534 
enriched pathways are shown. (C) RNAseq expression data for genes related to the IL-6 signaling pathway, 535 
Socs3 and Il6st. GCB: Germinal Center B-cells, B1: B1 B-cells, FOB: Follicular B-cells, MZB: Marginal 536 
Zone B-cells, SPLPC: Spleen Plasma-cells, BMPC: Bone Marrow Plasma-cells, SPLPB: Spleen 537 
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Plasmablasts (Shi et al., 2015), C-IM: GFP+hCD2+ C-IM cancer cells (FACS purified). (D) Representative 538 
flow cytometric analysis of the proliferation profiles illustrating the frequency of (pre)plasmablasts 539 
(CD138+) on day 2, 3, and 4 of LPS stimulation of B-cells from CD19cre IKK2castopFL MYCstopFL 540 
(IKK2caMYC) in vitro, in the presence of either control antibody (control Ig) or ant-IL6 neutralizing (anti-541 
IL6). Cell Trace Violet (CTV) dye dilution was used to assess proliferation. (E) MFI of pSTAT3 in 542 
B220lowCD138+ (pre)plasmablasts at day 2 of in vitro culture of B-cells from the indicated genotypes. Black 543 
circles represent control mice (WT), yellow circles CD19cre IKK2castopFL mice (IKK2), blue circles 544 
CD19cre MYCstopFL (MYC), and red circles CD19cre IKK2castopFL MYCstopFL (IKK2MYC). White 545 
background: control Ig, dashed background: anti-IL6. (F) Fold change (anti-IL6/control Ig) of the fraction 546 
of cleaved caspase 3+ cells within B220lowCD138+ (pre)plasmablasts at day 2 of in vitro culture of B-cells 547 
from the indicated genotypes as in (E). (G) MFI of BCL-xL in B220lowCD138+ (pre)plasmablasts at day 2 548 
of in vitro culture of B-cells from the indicated genotypes as in (E). White background: control Ig, dashed 549 
background: anti-IL6. (H) MFI of MCL-1 in B220lowCD138+ (pre)plasmablasts at day 2 of in vitro culture 550 
of B-cells from the indicated genotypes as in (E). White background: control Ig, dashed background: anti-551 
IL6. (I) Principal component (PC) analysis plots of RNA-seq analysis of activated B cells (B220+) and 552 
B220lowCD138+ (pre)plasmablasts at day 3 of in vitro culture of B-cells from CD19cre IKK2castopFL 553 
MYCstopFL (IKK2.MYC). (J) Enrichment for genes in the signature “Hallmark_Apoptosis” using GSEA 554 
and the GEP of B220lowCD138+ (pre)plasmablasts at day 3 of in vitro culture of B-cells from CD19cre 555 
IKK2castopFL MYCstopFL in the presence of control Ig (IKK2.MYC control Ig) or ant-IL6 antibody 556 
(IKK2.MYC anti IL6). (K) Cancer free survival curve for C-IM mice treated with control Ig (solid red line) 557 
or ant-IL6 antibody (dashed red line).  558 
 559 
Figure 6. IL6 is critical for the formation of NF-kB+MYC+ cancers at a poorly-differentiated Plasma-560 
cell state. See also Fig S4. 561 
(A) Representative flow cytometric analysis of Cre-mediated recombination in in spleen of C-IM and C-562 
IM-IL6KO mice at day 100 after the first tamoxifen administration (protocol of study as in Fig. 1C). (B) 563 
Frequency in spleen of reporter positive populations: GFPneghCD2+ i.e. MYC+, GFP+hCD2neg i.e. IKK2ca+, 564 
and GFP+hCD2+ i.e. IKK2ca+MYC+. (C) Frequency in spleen of CD19lowCD138+ cells within each reporter 565 
positive populations as in (B) and within reporter negative cells. (D) Frequency in spleen of cleaved caspase 566 
3+ CD19lowCD138+ cells within each reporter positive populations as in (B) and within reporter negative 567 
cells. (E) Frequency in spleen of CD19lowCD138+ cells at the S/G2M phase of the cell cycle within each 568 
reporter positive populations as in (B) and within reporter negative cells. (F) Cancer free survival curve for 569 
C-IM and C-IM-IL6KO mice. (G) Frequency of cleaved caspase-3+ within CD19lowCD138+ cancer cells of 570 
spleen of C-IM and C-IM-IL6KO. (H) Enrichment for genes in the signature “Hallmark_Apoptosis” using 571 
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GSEA in the GEP of C-IM-IL6KO and C-IM cancer cells (GFP+hCD2+ FACS sorted). (I) Transcriptional 572 
analysis of C-IM and C-IM-IL6KO cancer cells compared to discrete B-cell and Plasma-cell populations by 573 
RNAseq. GCB: Germinal Center B-cells, B1: B1 B-cells, FOB: Follicular B-cells, MZB: Marginal Zone 574 
B-cells, SPLPC: Spleen Plasma-cells, BMPC: Bone Marrow Plasma-cells, SPLPB: Spleen Plasmablasts 575 
(Shi et al., 2015). Seven C-IM and six C-IM-IL6KO cancers are depicted.  B-cell signature: expression 576 
profile of the top 50 downregulated genes in BMPCs compared with FoBs, Plasma-cell signature: 577 
expression profile of the top 50 upregulated genes in BMPCs compared to FOBs, in addition to 4 genes of 578 
particular immunological interest (Slc3a2, Prdm1, Ly6c1, Cd28). Log2 FPKM expression values of genes 579 
are shown in the heatmaps, color-coded according to the legend. (J) Analysis of clonality by RNA 580 
sequencing. The fraction of reads mapped to each individual IgH-V gene out of all the reads mapped to 581 
IgH-V genes is shown (Shi et al., 2015). Top panel: a GFP+hCD2+ C-IM-IL6KO B-cell cancer, bottom 582 
panel: a GFP+hCD2+ C-IM-IL6KO Plasma-cell cancer. (K) Enrichment for genes in the signature 583 
“Bcell_signature_Shi” using GSEA of the GEP of C-IM and C-IM-IL6KO (B-cell cancers) cancer cells. (L) 584 
RNAseq expression data for factors related to Plasma-cell differentiation (Prdm1, Irf4, Xpb1) and B-cell 585 
identity (Pax5) in cancer cells of C-IM and C-IM-IL6KO (B-cell cancers). (M) Enrichment for genes in the 586 
signature “Plasmablast_signature_Shi” using GSEA of the GEP of C-IM and C-IM-IL6KO (Plasma-cell 587 
cancers) cancer cells. (N) RNAseq expression data for factors related to Plasma-cell differentiation (Prdm1, 588 
Irf4, Xpb1) and B-cell identity (Pax5) in cancer cells of C-IM and C-IM-IL6KO (Plasma-cell cancers). 589 
 590 
Figure 7. NF-kB/MYC+ cancers are alike a fraction of PBL and linked to t(8;14)[MYC- IGH] MM at 591 
the gene expression level. See also Fig S5. 592 
(A) Enrichment for genes in the signature “Plasmablast_signature_Shi” (left) and “PC_signature_Shi” 593 
(right) using GSEA of the GEP of B220lowCD138+ (pre)Plasmablasts at day 3 of in vitro culture of B-cells 594 
from CD19cre IKK2castopFL and CD19cre IKK2castopFL MYCstopFL mice. (B) RNAseq expression data for 595 
factors related to Plasma-cell differentiation (Prdm1, Irf4, Xpb1) and B-cell identity (Pax5) in 596 
B220lowCD138+ (pre)Plasmablasts at day 3 of in vitro culture of B-cells from CD19cre IKK2castopFL and 597 
CD19cre IKK2castopFL MYCstopFL mice. (C) Left, representative immunohistochemical analysis of human 598 
biopsies of tonsil and PBL for MYC, nuclear NF-kB p50, nuclear NF-kB p52, and phospho STAT3 599 
(pSTAT3). A cutoff of >30% positive cells was used to determine positivity. Right, cumulative data of the 600 
immunohistochemical analysis. (D) Correlation between the gene enrichment of the “Myc.IKK2.muTex” 601 
signature with MM patient overall survival (left)  and progression free survival (right; MMRF dataset). (E) 602 
Association between the “Myc.IKK2.muTex” signature and MM chromosomal abnormalities. 603 
 604 
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Supplemental Figure Legends. 606 
Supplemental Figure 1. Dynamics of reporter positive subpopulations over-time. 607 
(A) Representative flow cytometric analysis of Cre-mediated recombination in the blood of C-YFP, C-608 
MYC, C-IKK2, and C-IM at days 55, 95, 135, 175 after the first tamoxifen administration. (B) Fraction of  609 
cells within the individual reporter positive populations: YFP+ in C-YFP mice and GFPneghCD2+ i.e. MYC+, 610 
GFP+hCD2neg i.e. IKK2ca+, and GFP+hCD2+ i.e. IKK2ca+MYC+ in C-IM mice. Frequencies were 611 
normalized to day 55 after the first tamoxifen administration. (C) Left, fraction of GFPneghCD2+ i.e. MYC+ 612 
in C-MYC mice. Right,  fraction of GFP+hCD2neg i.e. IKK2ca+ in C-IKK2 mice. Frequencies were 613 
normalized to day 55 after the first tamoxifen administration. 614 
 615 
Supplemental Figure 2. Characterization of C-IM cancer properties. 616 
(A) Southern blot analysis of cancer clonality using a JH4 probe. Dashed red line represents germline IgH 617 
configuration. Red arrow denotes clonal IgH. (B) ELISA of total serum IgM, IgG1 and IgG2b concentration 618 
in aged C-YFP and C-IM mice. (C) Serum protein electrophoresis of representative samples from aged C-619 
YFP and C-IM. The position of albumin and of various globulin components of the serum is indicated.  620 
 621 
Supplemental Figure 3. (pre)Plasmablasts are a source of IL6 622 
(A) Representative flow cytometric analysis of intracellular staining for IL6 in in vitro day3 LPS stimulated  623 
B-cells from the indicated genotypes. Top panels: of activated B cells (B220+), Bottom panels: 624 
B220lowCD138+ (pre)Plasmablasts. (B) Distribution of B220lowCD138+ (pre)plasmablasts within each cell 625 
division as assessed by CTV dilution at day 4 of in vitro cultures in the presence of control Ig or anti-IL6 626 
neutralizing antibody. Control mice (WT), CD19cre MYCstopFL (MYC), CD19cre IKK2castopFL mice 627 
(IKK2ca), CD19cre IKK2castopFL MYCstopFL (IKK2MYC). 628 
 629 
Supplemental Figure 4. Analysis of C-IM-IL6KO mice. 630 
(A) Left, frequency in bone marrow of C-IM and C-IM-IL6KO mice at day 100 after first tamoxifen 631 
injection of reporter positive populations: GFPneghCD2+ i.e. MYC+, GFP+hCD2neg i.e. IKK2ca+, and 632 
GFP+hCD2+ i.e. IKK2ca+MYC+. Right, frequency in bone marrow of C-IM and C-IM-IL6KO mice at day 633 
100 after first tamoxifen injection of CD19lowCD138+ cells within each reporter positive populations and 634 
within reporter negative cells. (B) Representative histological and immunohistochemical analysis of a B-635 
cell cancer in the spleen of a C-IM-IL6KO mice (top panels) and of a Plasma-cell cancer in the spleen of C-636 
IM-IL6KO mice (bottom panels) for H&E, B220, Pax5, Irf4, and Ki67. 637 
 638 
Supplemental Figure 5. Gene signature enrichment in MM. 639 
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(A) Correlation between the enrichment of a “NF-kB signature” (PASQUALUCCI) and the “NF-kB 640 
signature” (STAUDT) with MM patient overall survival (MMRF dataset). (B) Correlation between the 641 
enrichment of a “STAT3 signature” (STAUDT) with MM patient overall survival (MMRF dataset). (C) 642 
Correlation between the enrichment of multiple MYC signatures with MM patient overall survival (MMRF 643 
dataset). (D) Venn diagram showing the overlap in genes upregulated in the GEP of B220lowCD138+ cells 644 
derived in vitro from B-cells of CD19cre IKK2castopFL mice (IKK2), CD19cre MYCstopFL (MYC), CD19cre 645 
IKK2castopFL MYCstopFL (IKK2MYC) mice. (E) Correlation between the enrichment of the “IKK2.muTex” 646 
signature with MM patient overall survival (left)  and progression free survival (right; MMRF dataset). 647 
Association between the “IKK2.muTex” signature and MM chromosomal abnormalities. (F) Correlation 648 
between the enrichment of the “Myc.muTex” signature with MM patient overall survival (left)  and 649 
progression free survival (right; MMRF dataset). Association between the “Myc.muTex” signature and 650 
MM chromosomal abnormalities. 651 
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Materials and methods 673 
Mouse models and tumor cohorts: CD19creERT2, CD19cre, IKK2castopFL, MYCstopFL, IL6KO/KO, and 674 
YFPstopFL alleles have been previously described. For T cell-dependent immunization, 8- to 12-675 
week old mice were injected intravenously with 109 defibrinated Sheep Red Blood Cells (SRBCs) 676 
(TCS Bioscience) in PBS. Mice were administered tamoxifen by oral gavage, dissolved in 677 
sunflower seed oil (both from Sigma). For full details on the experimental protocol, please see 678 
Figure 1E. Mouse cohorts were monitored twice a week for tumor development and euthanized if 679 
signs of tumor development occurred.  Experiments were conducted using age-matched animals. 680 
Sex/gender was randomly distributed. All mice were on the C57BL/6 background. Mice were bred 681 
at The Francis Crick Institute under specific pathogen-free conditions. All animal experiments 682 
were carried out in accordance with national and institutional guidelines for animal care and were 683 
approved by The Francis Crick Institute Biological Resources Facility Strategic Oversight 684 
Committee (incorporating the Animal Welfare and Ethical Review Body) and by the Home Office, 685 
UK. 686 
 687 
In vivo treatment with anti-IL6 neutralizing antibody: To study the impact of IL6 on cancer 688 
progression, C-IM mice were treated with InVivoMAb anti-mouse IL-6 (bioXcell), or a control 689 
antibody (InVivoMAb rat IgG1 isotype control, anti-horseradish peroxidase; bioXcell). 690 
Administration of the antibodies was performed intraperitoneally three times per week for three 691 
weeks, starting on day 150 after tamoxifen administration. Mice were given 200ug of antibody per 692 
injection, diluted in InVivoPure dilution buffer, as per manufacturer’s instructions. 693 
 694 
In vitro stimulations: B cells were isolated from splenocyte suspensions using CD43 microbeads 695 
(Miltenyi Biotec), and plated at a density of 1x106/mL in B-cell media (DMEM high glucose with 696 
Glutamax (Gibco), supplemented with Fetal Bovine Serum (GE Healthcare), non-essential 697 
aminoacids (Gibco), HEPES buffer (Gibco), sodium pyruvate (Gibco), Penicillin-Streptomycin 698 
(Gibco), and 2-Mercaptoethanol (Sigma-Aldrich)). B cells were stimulated with 699 
Lipopolysaccharide (LPS; Sigma-Aldrich) at a concentration of 10ug/mL. Where indicated, LPS 700 
stimulation was performed in the presence of blocking anti-IL-6 antibody or control IgG 701 
(Biolegend), at a concentration of 1ug/mL. 702 
 703 
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Histology and Immunohistochemistry: Mouse spleens were fixed with 10% neutral buffered 704 
formalin (NBF) (Fischer Scientific) and embedded in paraffin. Sections were stained with 705 
hematoxylin and eosin (H&E) (Sigma). Antigen retrieval was performed with citrate buffer pH6, 706 
23 minutes in the microwave. Ki67 staining was performed using the Ventana Discovery Ultra, 707 
CC1 for 48 minutes. All slides were counterstained with Harris Haematoxylin (Fisher Scientific), 708 
in Tissue Tek Prisma staining machine. Images were acquired with Zeiss Axio Scan.Z1 Slide 709 
Scanner and visualized with ZEN lite Blue Edition (Zeiss). For human Plasmablastic samples, 710 
tumor biopsies were fixed with 10% NBF and embedded in paraffin. Antigen retrieval (heat-711 
induced epitope retrieval) was performed with citrate buffer using a pressure cooker and a 712 
commercial unmasking solution (Vector labs). The detection system used was from Biogenex 713 
(Super Sensitive Polymer HRP IHC Detection System). Images were acquired with the 714 
Pannoramic 250 Flash Scanner, uploaded into an online server (Casecenter) and visualized using 715 
Pannoramic Viewer (all 3DHistec). 716 
 717 
Flow cytometry: Single-cell suspensions of spleen and bone marrow were prepared in FACS 718 
buffer (2% FBS, 2 mM EDTA), in PBS (Gibco) and were treated with ACK Lysing Buffer (Gibco) 719 
for erythrocyte lysis. Single-cell suspensions were stained with antibodies, see Key Resources 720 
Table for details. Dead cells were excluded using Zombie NIR™ Fixable Viability Kit 721 
(BioLegend). For the assessment of cell division, cells were stained with CellTraceTM Violet 722 
(Invitrogen) as per manufacturer’s specifications, prior to in vitro stimulation. For the detection of 723 
cleaved caspase-3, MCL1 and BCL-xL, samples were fixed for 20 min on ice after surface marker 724 
and viability dye staining, followed by intracellular staining using BD Cytofix/Cytoperm staining 725 
kit (BD Biosciences) as per manufacturer’s specifications. For the detection of STAT3 and 726 
phospho STAT3, samples were fixed for 15 min at 37ºC after surface marker and viability dye 727 
staining using Fixation Buffer (Biolegend), followed by permeabilization for 1h at -20ºC with 728 
True-PhosTM Perm Buffer (Biolegend) as per manufacturer’s specifications. For the detection of 729 
IL-6, cells were cultured in the presence of brefeldin A (Sigma) for 4h, followed by fixation for 730 
15 min at room temperature in 4% paraformaldehyde (Thermo Fisher). Samples were acquired on 731 
an LSR-Fortessa (BD Biosciences) with FACS-Diva software (BD Biosciences) and data were 732 
analyzed with FlowJo software (v10.3, Tree Star). 733 
 734 
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Gene expression analysis: For gene expression profiling of C-IM and C-IM-IL6KO tumors, 735 
reporter positive cells (GFP+ hCD2+) were FACS sorted using a FACSAria III or a FACSAria 736 
Fusion (BD Biosciences). For gene expression profiling of in vitro derived activated B cells and 737 
plasmablasts, cells were FACS sorted at day 3 of LPS stimulation according to the expression of 738 
CD19 and CD138 markers (activated B cells – CD19+ CD138neg; plasmablasts – CD19low 739 
CD138+). RNA was extracted using AllPrep DNA/RNA Mini and Micro Kits (Qiagen) as per 740 
manufacturer’s specifications. RNA sequencing was performed at The Francis Crick Institute 741 
Advanced Sequencing Unit. RNA sequencing was carried out on the Illumina HiSeq 2500 and 742 
4000 platforms and typically generated around 25 million 101bp strand-specific paired-end reads 743 
per sample. Adapter trimming was performed with cutadapt (version 1.9.1) (Martin M, 2011) with 744 
parameters “--minimum-length=25 --quality-cutoff=20 -a AGATCGGAAGAGC –A 745 
AGATCGGAAGAGC”. The RSEM package (version 1.3.0) (Li and Dewey, 2011) in conjunction 746 
with the STAR alignment algorithm (version 2.5.2a) (Dobin et al., 2013) was used for the mapping 747 
and subsequent gene-level counting of the sequenced reads with respect to mm10 Ensembl genes 748 
downloaded from the UCSC Table Browser (Karolchik et al., 2004) on 19th February 2016. The 749 
parameters used were “--star-output-genome-bam –paired-end --forward-prob 0”. Differential 750 
expression analysis was performed with the DESeq2 package (version 1.12.3) (Love et al., 2014) 751 
within the R programming environment (version 3.3.1) (REF). An adjusted p-value of <= 0.05 was 752 
used as the significance threshold for the identification of differentially expressed genes. The 753 
Subjunc aligner from the Subread package (version 1.5.1) (Liao et al., 2013) was used for the 754 
quantification of Ighv transcripts as described in Shi et al., 2015. The parameters used were “--755 
allJunctions -I 16 -u”. Gene set enrichment analysis (GSEA) (version 2.2.3) (Subramanian et al., 756 
2005) pre-ranked analysis was performed using the Wald statistic with respect to custom signatures 757 
obtained from the literature. All parameters were kept as default except for enrichment statistic 758 
(classic), min size (5) and max size (50 000). Gene set enrichment analysis for differentially 759 
expressed genes was performed by Gene Ontology Pathway and Biological processes using 760 
GeneGo MetaCore (https://portal.genego.com/). 761 
 762 
Quantitative real time PCR: Total RNA was reverse transcribed using the SuperScript® III First-763 
Strand Synthesis System with Oligo(dT)20 (Invitrogen). For qRT-PCR analysis, the Power SYBR 764 
Green Master Mix was used, followed by quantification with the StepOnePlus System (Applied 765 
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Biosystems). Samples were assayed in duplicate, and messenger abundance was normalized to that 766 
of HPRT1. Primers sequences used for Prdm1, Xbp1, Sdc1 and Irf4 amplification can be found in 767 
the table attached. 768 
 769 
Statistical analyses: Data were analyzed using unpaired two-tailed Mann-Whitney test for two-770 
way comparisons. Statistical significance for multiple comparisons was calculated using the False 771 
Discovery Rate approach by using the Two-Stage Step-Up method of Benjamini, Krieger and 772 
Yekutieli. P-value of 0.05 or less was considered significant. Prism (v8, GraphPad) was used for 773 
statistical analysis. Data in text and figures are represented as box plots with floating bars 774 
representing min and max values, with median value represented as a line. 775 
 776 
Analysis of tumor clonality: Southern blotting of EcoRI-digested genomic DNA from C-IM 777 
tumors using a JH probe spanning the JH4 exon and part of the downstream intronic sequence. 778 
 779 
Serum protein electrophoresis: Serum from C-IM tumor mice and C-EYFP aged mice was 780 
diluted 1:2 in barbital buffer and analyzed on a Hydragel K20 system (Sebia) according to 781 
manufacturer's instruction. 782 
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